Clinical Cancer Research · 2014 · 57 citations · 45 references
MedicineOncologyPathologyCellular PathologyHistopathologyImmunopathologyHelper T Cell SubsetsHematologic MalignanciesLymphoid NeoplasmsLymphoid TissueLymphoid TumorsT Cell BiologyCd4+ Tumor-infiltrating LymphocytesCell Proliferation IndicesFlow Cytometry ImmunophenotypingHistologic ExaminationLymphoma GradingLymphoma HistopathologyPrognostic Factors Analysis
PURPOSE: The purpose of this study was to investigate the impact of T-cell subsets on pathologic and clinical features including disease outcome in mantle cell lymphoma (MCL). EXPERIMENTAL DESIGN: Cell populations were investigated using flow cytometry in diagnostic MCL (n = 153) and reactive (n = 26) lymph node biopsies. Levels of tumor cells, T cells, T-cell subsets, and the CD4:CD8 ratio were assessed and related to pathologic and clinical parameters. RESULTS: MCL cases with diffuse and nodular histologic subtypes showed lower levels of T cells, especially CD4(+) T cells, than those with mantle zone growth pattern. Both CD3 and CD4 levels were lower in the nodular subtype than in mantle zone (P = 0.007; P = 0.003) and in the diffuse compared with the nodular subtype (P = 0.022; P = 0.015). The CD4:CD8 ratios were inversely correlated to tumor cell proliferation (P = 0.003). Higher levels of CD3(+) and CD4(+) T cells and higher CD4:CD8 ratios were associated with indolent disease (P = 0.043, 0.021, and 0.003 respectively). In univariate analysis, a high CD4:CD8 ratio, but not the histologic subtype, was correlated to longer overall survival (OS). In multivariate analysis, the CD4:CD8 ratio correlated with OS independently of Mantle Cell Lymphoma International Prognostic Index (MIPI) and high p53 expression (P = 0.023). CONCLUSION: CD3(+), CD8(+), and particularly CD4(+) T-cell levels are higher in indolent MCL and decrease with more aggressive histology as reflected by a diffuse growth pattern. High CD4:CD8 ratio correlated independently of other high-risk prognostic factors with longer OS, suggesting a prognostic role for T cells in MCL.
45
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text
Medicine, Hematology, Pharmacology +17
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster, Martin Dreyling, Christian Gisselbrecht et al. · Blood · 2007 · 971 citations
Medicine, Hematology, Oncology +11
Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2008 · 624 citations · Full text
Medicine, Hematology, Oncology +13